Stewart Washer says Zelda Therapeutics is catching up with market use, given the nature of cannabis regulation. Photo: Attila Csaszar

Zelda in cannabis autism trial

Perth-based clinical trials company Zelda Therapeutics is growing its global medicinal cannabis operations as the scope of the sector broadens, embarking on a program of human trials targeting sleep disorders, autism and eczema.


(existing subscribers)

The password field is case sensitive.
Request new password

Add your comment

Share Price

Closing price for the last 90 trading days
Source: Morningstar

Total Shareholder Return as at 29/06/18

1 year TSR5 year TSR
69thBotanix Pharmaceuticals164%106%
271stEve Investments33%16%
342ndZelda Therapeutics22%43%
631stCervantes Corporation-25%56%
722 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar

Share Transactions

$495k Sold
Total value as at the date of the transaction
Source: Morningstar


185th↑Zelda Therapeutics$100k
209th↓Eve Investments$245
211th↓Botanix Pharmaceuticals$0
212th↓Cervantes Corporation$0
239 listed industrial companies ranked by revenue.
Source: Morningstar

BNiQ Disclaimer